Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial.

CONCLUSIONS: At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab. PMID: 32594522 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32594522?dopt=Abstract

Source: The British Journal of Dermatology - June 27, 2020 Category: Dermatology Authors: Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C Tags: Br J Dermatol Source Type: research